Optimization of Electrofusion Parameters for Producing Hybridomas Synthesizing Human Monoclonal Antibodies

Monoclonal antibodies are an established treatment for many illnesses, including cancer, toxicity and infectious diseases. The goal of this work was to optimize the conditions for obtaining hybridomas secreting human monoclonal IgG antibodies. A new protocol has been developed for efficient electrofusion of human B lymphocytes with partner cells. Electrofusion parameters were optimized, and the preferred partner cell line and ratio of cells involved in the fusion were selected. Two myeloma cell lines, K6H6/B5 and SHM-D33, were tested in detail, and the highest fusion efficiency was observed for K6H6/B5. Three hybridomas that secreted fully human monoclonal IgG antibodies were obtained using the optimized electrofusion protocol; the secretion of antibodies was observed for 1 month, which indicates the stability of the clones and the absence of chromosome segregation.